Collegium Pharmaceutical (FRA:354) Long-Term Debt: €666.2 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:354 Collegium Pharmaceutical Inc FRA:354
76 GF Score
Price €30.80
GF Value €36.97
! 3 Warning Signs
View Full Analysis

What is Collegium Pharmaceutical Long-Term Debt?

Collegium Pharmaceutical FRA:354 -0.65% 76 Long-Term Debt is €666.2 Mil as of Mar. 2026. GuruFocus rates FRA:354 with a GF Score™ of 76/100 and a GF Value™ of €36.97. The stock has 3 warning signs investors should review.

Collegium Pharmaceutical's Long-Term Debt for the quarter that ended in Mar. 2026 was €666.2 Mil.

Collegium Pharmaceutical's quarterly Long-Term Debt increased from Sep. 2025 (€633.5 Mil) to Dec. 2025 (€666.4 Mil) but then declined from Dec. 2025 (€666.4 Mil) to Mar. 2026 (€666.2 Mil).

Collegium Pharmaceutical's annual Long-Term Debt increased from Dec. 2023 (€443.7 Mil) to Dec. 2024 (€752.4 Mil) but then declined from Dec. 2024 (€752.4 Mil) to Dec. 2025 (€666.4 Mil).

Collegium Pharmaceutical  (FRA:354) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Collegium Pharmaceutical Long-Term Debt Related Terms

Collegium Pharmaceutical Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Collegium Pharmaceutical's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Collegium Pharmaceutical Long-Term Debt Chart

Collegium Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 178.44 508.30 443.68 752.45 666.40

Collegium Pharmaceutical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 715.14 657.48 633.49 666.40 666.22
FRA:354
76GF Score
Collegium Pharmaceutical Inc FRA:354
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €666.2 Mil mean?
Collegium Pharmaceutical (FRA:354) has a Long-Term Debt of €666.2 Mil as of Mar. 2026.
Is Collegium Pharmaceutical's Long-Term Debt too high?
Collegium Pharmaceutical's current Long-Term Debt is €666.2 Mil. Overall, Collegium Pharmaceutical has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Collegium Pharmaceutical's Long-Term Debt compare to ALVO and PAHC?
Collegium Pharmaceutical's Long-Term Debt of €666.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Collegium Pharmaceutical's current Long-Term Debt is €666.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Collegium Pharmaceutical stock overvalued right now?
Collegium Pharmaceutical (FRA:354) has a current Long-Term Debt of €666.2 Mil. The stock's GF Value™ is €36.97, compared to a current price of €30.80 — trading 16.7% below its estimated fair value. The current Long-Term Debt is €666.2 Mil. Collegium Pharmaceutical's overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Collegium Pharmaceutical (FRA:354), the current Long-Term Debt is €666.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Collegium Pharmaceutical (FRA:354) Overvalued in 2026?

Based on GuruFocus' analysis, Collegium Pharmaceutical stock appears to be undervalued. The current stock price of €30.80 is trading 16.7% below its estimated GF Value™ of €36.97.

Key valuation signals for FRA:354:

  • Long-Term Debt: €666.2 Mil
  • GF Value™: €36.97 vs. price of €30.80 (16.7% below fair value)
  • GF Score™: 76/100 with 3 warning signs

No single metric tells the full story. See the FRA:354 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Collegium Pharmaceutical Business Description

Other Exchanges COLL:USA354:Germany
Address 100 Technology Center Drive, Stoughton, MA, USA, 02072
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
76GF Score

Get the complete analysis for FRA:354

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€30.80
Price
€36.97
GF Value